hVIVO plc (LON: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hLAB, the Group’s standalone virology and immunology laboratory service provider, has signed a new £2.7m contract with a US-based biotechnology client bringing the total value of this project to date to £3.2m.
As part of this new contract, hLAB will act as the only contracted virology lab for an international, multi-site Phase 2 field study for the US biotechnology client’s influenza drug candidate. Study work will commence immediately and hLAB will provide virology and immunology lab services across the 5,000 subjects recruited in this trial. Although hVIVO has provided virology and immunology laboratory services for its internal challenge trials for over 20 years, this is the largest standalone laboratory services contract signed by the Company to date. The majority of the revenue from this contract is expected to be recognised in 2025 with the remainder in 2026. The earlier contract commenced in H2 2024.
